Fall and cellulitis

Apixaban and Atrial fibrillation

Clindamycin and RLE cellulitis

Switching from warfarin to apixaban: Discontinue warfarin and start apixaban when the INR is less than 2.
Switching from apixaban to warfarin: Discontinue apixaban and start a parenteral anticoagulant plus warfarin 5 mg at the time of the next apixaban dose; discontinue the parenteral anticoagulant when INR reaches a therapeutic range

Comments

Sodium chloride Tablets USP

A 91- year old patient. Admitted to the hospital from the ED. Patient was seen for altered mental status. Labs, CT of brain head, CXR XR of left Tib/Fib were performed. Presumed meningioma in the left middle cranial fossa was noted. Sodium was critically low at 114. Nephrologist was consulted and hyponatremia is of unknown etiology. Patient also has uncontroled hypertension. Comorbidities: Coronary artery disease, Diabetes, Dementia, hypothyroidism, hyperlipedemia, neuropathy. Patient will need physicain oversight for hyponatremia, normal saline routinely, and medication management for hypertension. Rx: Sodium Chloride USP 1.0 gram Use 1. Hyponatremia 2. Preparation of normal isotonic solution of sodium chloride 3. As an electrolyte replenisher for the prevention of heat cramps, due to excessive perspiration 4. any alternate use as directed by a physician Each tablet contains: sodium 394mg Hyponatremia is a common electrolyte disorder encountered i...

Mounjaro, Is it a game changer for weight loss and diabetes?

MOUNJARO™ ( Tirzepatide) was approved for medical use in the United States in May 2022 WEIGHT LOSS: (Not approved by FDA for weight loss) Eli Lilly and Company is finalizing an application to the U.S. Food and Drug Administration for fast-track approval to sell tirzepatide for chronic weight management. MOUNJARO™ is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated in adults for type 2 diabetes mellitus management. CONTRAINDICATIONS Personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2 Known serious all to tirzepatide or any of the excipients in MOUNJARO ...

Heart healthy

*Clinical atherosclerotic cardiovascular disease (ASCVD) includes acute coronary syndrome (ACS), those with history of myocardial infarction (MI), stable or unstable angina or coronary or other arterial revascularization, stroke, transient ischemic attack (TIA), or peripheral artery disease (PAD) including aortic aneurysm, all of atherosclerotic origin. Should I initiate statins or not? The 2014 National Lipid Association (NLA) recommendations provides a more comprehensive, patient-centered approach to identifying ASCVD risk. In 2013, the American College of Cardiology and the American Heart Association (ACC/AHA) issued guidelines to use the intensity of statin therapy as the treatment goal instead of LDL-C or non–HDL-C targets, as in previous guidelines, to reduce atherosclerotic cardiovascular disease (ASCVD) risk ( Andrus & Lacaille, 2014 ) The guideline classifies statin therapy as high-intensity (lowers LD...

Real Time Pharmacology

Search This Blog